Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 3 4Phase 1/2 4Phase 1 4Phase 2/3 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Conditions

Neoplasms 314Carcinoma, Non-Small-Cell Lung 162Breast Neoplasms 125Neoplasm Metastasis 106Melanoma 95Leukemia, Myeloid, Acute 80Lymphoma 79Multiple Myeloma 74Colorectal Neoplasms 73Ovarian Neoplasms 70Lymphoma, Non-Hodgkin 63Recurrence 58Prostatic Neoplasms 56Pancreatic Neoplasms 51Lung Neoplasms 50Carcinoma, Renal Cell 40Glioblastoma 39Precursor Cell Lymphoblastic Leukemia-Lymphoma 38Lymphoma, Large B-Cell, Diffuse 37Leukemia, Lymphocytic, Chronic, B-Cell 37Advanced Solid Tumors 37Leukemia 36Myelodysplastic Syndromes 35Triple Negative Breast Neoplasms 34Head and Neck Neoplasms 33Sarcoma 31Brain Neoplasms 31Urinary Bladder Neoplasms 30Stomach Neoplasms 30Lymphoma, Follicular 28

Interventions

berzosertib 2serabelisib 1cobimetinib 1Topotecan 12-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Has results × Hereditary Sensory and Autonomic Neuropathies × Clear all
NCT03309150 2024-11-29

ATRi Transition Rollover Study

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
1 enrolled 4 charts

Hereditary Sensory and Autonomic Neuropathies

NCT05246111 2024-11-22

Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 1 Completed
6 enrolled 30 charts

Hereditary Sensory and Autonomic Neuropathies

NCT01449370 2017-03-09

Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer

Takeda

Phase 1 Completed
125 enrolled 46 charts

Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT00996892 2016-12-30

Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors

Genentech, Inc.

Phase 1 Terminated
178 enrolled 102 charts

Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡